Q1 2026 Orion Oyj Earnings Call Transcript
Key Points
- Orion Oyj (ORINF) reported a healthy net sales growth of almost 18% compared to the previous year's Q1.
- Operating profit increased by 47%, resulting in an operating profit margin of 27.5%.
- Earnings per share also saw a significant increase of 47%.
- The Innovative Medicines division experienced a growth of close to 54%, driven by Nubeqa royalties and tablet sales.
- Orion Oyj (ORINF) has been able to decrease its greenhouse gas emissions by 13% in Scope 1 and 2.
- There is a noted effect of decreasing prices impacting major products like Simdax and Dexdor.
- Generics and Consumer Health growth was only 1.4%, slightly below market growth.
- The injury rate at Orion Oyj (ORINF) is 4.9, indicating room for improvement in safety.
- Burana sales decreased by almost 6%, attributed to timing issues and seasonal factors.
- Simdax is facing heavy generic competition in Europe, affecting its sales performance.
Good afternoon, and welcome to Orion's Q1 2026 results webcast and conference call. My name is Tuukka Hirvonen, and I'm the Head of IR here at Orion. In a few moments, we will kick off with the presentation by our CEO, Liisa Hurme, after which you will have the possibility to ask questions either from Liisa or from our CFO, Rene Lindell.
We will be first taking the questions through the conference call lines. And after that, we will turn on to the webcast chat function. So you may also type in your questions using the chat function of this webcast. And to our Finnish-speaking viewers, this event is held in English. But afterwards, later this afternoon, you will find a Finnish interview of Orion's CEO, Liisa Hurme on Orion's website.
And just before letting Liisa to step in, just a reminder about this disclaimer regarding forward-looking statements.
With these words, I'd like to hand over to Liisa.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
